| 1 |
34547305 | Coupling EGFR-Antagonistic Affibody Enhanced Therapeutic Effects of Cisplatin Liposomes in EGFR-expressing Tumor Models. | 2022 Feb |
3 |
| 2 |
35238281 | BEZ235 reduction of cisplatin resistance on wild-type EGFR non-small cell lung cancer cells. | 2022 Mar 3 |
2 |
| 3 |
35241559 | Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer. | 2022 Mar-Apr |
1 |
| 4 |
33111200 | Transcriptome analysis of the circadian clock gene BMAL1 deletion with opposite carcinogenic effects. | 2021 Jan |
1 |
| 5 |
33169187 | Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed. | 2021 Mar |
1 |
| 6 |
33332190 | Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. | 2021 Mar 1 |
2 |
| 7 |
33613698 | A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study). | 2021 |
1 |
| 8 |
33794187 | FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer. | 2021 Aug |
1 |
| 9 |
33994369 | Cisplatin Activates the Growth Inhibitory Signaling Pathways by Enhancing the Production of Reactive Oxygen Species in Non-small Cell Lung Cancer Carrying an EGFR Exon 19 Deletion. | 2021 May-Jun |
1 |
| 10 |
34023418 | GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling. | 2021 Aug 28 |
1 |
| 11 |
34026617 | Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers. | 2021 |
1 |
| 12 |
34061460 | Lung squamous cell carcinoma with severe hypomagnesemia due to cisplatin plus gemcitabine in combination with necitumumab therapy: A case report. | 2021 Jul |
2 |
| 13 |
34065402 | KRAS and EGFR Mutations Differentially Alter ABC Drug Transporter Expression in Cisplatin-Resistant Non-Small Cell Lung Cancer. | 2021 May 20 |
3 |
| 14 |
34068624 | Targeting SIRT2 Sensitizes Melanoma Cells to Cisplatin via an EGFR-Dependent Mechanism. | 2021 May 10 |
1 |
| 15 |
34123574 | Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness. | 2021 Jun 1 |
1 |
| 16 |
34294133 | Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors. | 2021 Jul 22 |
3 |
| 17 |
34359721 | Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic Stress. | 2021 Jul 29 |
2 |
| 18 |
34410944 | Induction of Apoptosis and Inhibition of EGFR/NF-κB Signaling Are Associated With Regorafenib-sensitized Non-small Cell Lung Cancer to Cisplatin. | 2021 Sep-Oct |
5 |
| 19 |
34873481 | MEK1/2 regulates APOBEC3B and polymerase iota-induced mutagenesis in head and neck cancer cells. | 2021 |
1 |
| 20 |
34917992 | Response to Icotinib Plus Chemotherapy in Pulmonary Atypical Carcinoid Harboring the EGFR L858R Mutation: A Brief Report. | 2021 Dec |
2 |
| 21 |
34976847 | Adding Concurrent Chemotherapy Significantly Improves the Survival of Stage II-IVb Nasopharyngeal Carcinoma Patients Treated With Concurrent Anti-EGFR Agents. | 2021 |
1 |
| 22 |
35070983 | Prediction of the Mechanisms by Which Quercetin Enhances Cisplatin Action in Cervical Cancer: A Network Pharmacology Study and Experimental Validation. | 2021 |
1 |
| 23 |
31814556 | Ginsenoside Rh2 Improves the Cisplatin Anti-tumor Effect in Lung Adenocarcinoma A549 Cells via Superoxide and PD-L1. | 2020 |
1 |
| 24 |
31856423 | Harnessing the Potential Synergistic Interplay Between Photosensitizer Dark Toxicity and Chemotherapy. | 2020 May |
1 |
| 25 |
31881486 | Circular RNA CDR1-AS contributes to pemetrexed and cisplatin chemoresistance through EGFR/PI3K signaling pathway in lung adenocarcinoma. | 2020 Mar |
5 |
| 26 |
31959339 | Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). | 2020 Feb |
2 |
| 27 |
32236608 | CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wild‑type non‑small‑cell lung cancer cells. | 2020 Jun |
5 |
| 28 |
32269724 | Exploring cisplatin resistance in ovarian cancer through integrated bioinformatics approach and overcoming chemoresistance with sanguinarine. | 2020 |
1 |
| 29 |
32342201 | Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. | 2020 Jul |
7 |
| 30 |
32389961 | [Effects of Oral Magnesium and Antacid Administration on Serum Magnesium Levels and Renal Function in Patients Receiving Cisplatin]. | 2020 Apr |
2 |
| 31 |
32434541 | Cisplatin treatment induced interleukin 6 and 8 production alters lung adenocarcinoma cell migration in an oncogenic mutation dependent manner. | 2020 May 20 |
1 |
| 32 |
32641710 | Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy. | 2020 Jul 8 |
1 |
| 33 |
32660222 | EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells. | 2020 Nov |
3 |
| 34 |
32806648 | Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells. | 2020 Aug 12 |
1 |
| 35 |
33015030 | Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance. | 2020 |
1 |
| 36 |
33197924 | Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations. | 2020 |
1 |
| 37 |
33353547 | CAFs affect the proliferation and treatment response of head and neck cancer spheroids during co-culturing in a unique in vitro model. | 2020 Dec 22 |
1 |
| 38 |
30229902 | Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation. | 2019 May |
1 |
| 39 |
30417422 | Inactivation of ADAMTS18 by aberrant promoter hypermethylation contribute to lung cancer progression. | 2019 May |
3 |
| 40 |
30423706 | Targeting graphene quantum dots to epidermal growth factor receptor for delivery of cisplatin and cellular imaging. | 2019 Jan 1 |
5 |
| 41 |
30449625 | Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. | 2019 Jan 5 |
1 |
| 42 |
30664215 | Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFR‑Akt pathway. | 2019 Mar |
1 |
| 43 |
30815759 | GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer. | 2019 Sep |
1 |
| 44 |
31138260 | Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. | 2019 May 28 |
2 |
| 45 |
31142791 | Mechanistic Study of TTF-1 Modulation of Cellular Sensitivity to Cisplatin. | 2019 May 29 |
1 |
| 46 |
31161851 | Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report. | 2019 |
1 |
| 47 |
31171399 | Gefitinib with or without Transarterial Infusion Chemotherapy (Cisplatin) for Large Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations. | 2019 Jul |
1 |
| 48 |
31189612 | Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake. | 2019 Aug |
1 |
| 49 |
31262325 | The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens. | 2019 Jul 1 |
1 |
| 50 |
31289485 | Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin. | 2019 Jul |
1 |